当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
36期
136-137
,共2页
福莫特罗%布地奈德%联合用药%慢性阻塞性肺疾病%急性加重期
福莫特囉%佈地奈德%聯閤用藥%慢性阻塞性肺疾病%急性加重期
복막특라%포지내덕%연합용약%만성조새성폐질병%급성가중기
Formoterol%Budesonide%Combination therapy%Chronic obstructive pulmonary disease%Acute exacerbations
目的:研究布地奈德联合福莫特罗治疗慢性阻塞性肺疾病急性加重期的疗效。方法选择2010年4月-2012年12月收治的慢性阻塞性肺疾病急性加重期患者90例,随机分为观察组与对照组,各45例,两组均予以常规治疗,观察组在此基础上给予布地奈德联合福莫特罗治疗,对照组则给予福莫特罗治疗,比较两组疗效。结果观察组的总有效率为93.33%(42/45),对照组为80.00%(36/45),观察组显著高于对照组(P<0.05);治疗后观察组FEV1、FEV1/FVC均显著高于对照组(P<0.05),PaO2和PaCO2均显著低于对照组(P<0.05)。结论布地奈德联合福莫特罗治疗慢性阻塞性肺疾病急性加重期的疗效明显优于单一用药,并且安全可靠,值得临床推广。
目的:研究佈地奈德聯閤福莫特囉治療慢性阻塞性肺疾病急性加重期的療效。方法選擇2010年4月-2012年12月收治的慢性阻塞性肺疾病急性加重期患者90例,隨機分為觀察組與對照組,各45例,兩組均予以常規治療,觀察組在此基礎上給予佈地奈德聯閤福莫特囉治療,對照組則給予福莫特囉治療,比較兩組療效。結果觀察組的總有效率為93.33%(42/45),對照組為80.00%(36/45),觀察組顯著高于對照組(P<0.05);治療後觀察組FEV1、FEV1/FVC均顯著高于對照組(P<0.05),PaO2和PaCO2均顯著低于對照組(P<0.05)。結論佈地奈德聯閤福莫特囉治療慢性阻塞性肺疾病急性加重期的療效明顯優于單一用藥,併且安全可靠,值得臨床推廣。
목적:연구포지내덕연합복막특라치료만성조새성폐질병급성가중기적료효。방법선택2010년4월-2012년12월수치적만성조새성폐질병급성가중기환자90례,수궤분위관찰조여대조조,각45례,량조균여이상규치료,관찰조재차기출상급여포지내덕연합복막특라치료,대조조칙급여복막특라치료,비교량조료효。결과관찰조적총유효솔위93.33%(42/45),대조조위80.00%(36/45),관찰조현저고우대조조(P<0.05);치료후관찰조FEV1、FEV1/FVC균현저고우대조조(P<0.05),PaO2화PaCO2균현저저우대조조(P<0.05)。결론포지내덕연합복막특라치료만성조새성폐질병급성가중기적료효명현우우단일용약,병차안전가고,치득림상추엄。
Objective To study the effects of Budesonide joint Formoterol in treatment of acute exacerbations of chronic obstructive pulmonary disease(AECOPD).Methods 90 cases with AECOPD in our hospital between April 2010 and December 2012 were studied, Randomly divided into observation group and control group, 45 cases in each group, Both groups were treated with routine treatment, the observation group on the basis of budesonide formoterol combination therapy, the control group were treated with Formoterol , compared the clinical efficacy of the two groups. Results The total effective rate of observation group was 93.33% (42/45), that in the control group was 80.00% (36/45), the observation group was significantly higher (P<0.05); After treatment, FEV1, FEV1/FVC of observation group were significantly higher than the control group (P <0.05), PaO2 and PaCO2 were significantly lower than the control group (P<0.05).Conclusion The efficacy of Budesonide joint Formoterol in treatment of AECOPD is significantly better than monotherapy, and safe and reliable, worthy of promotion.